TLR

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Retrieved on: 
Monday, October 23, 2023
CR, Memorial Sloan Kettering Cancer Center, PRS, Trastuzumab, Plasma, Cholangiocarcinoma, Aes, ESMO, ISAC, MPH, Nivolumab, Publication, HER2, Congress, LVEF, Salivary gland tumour, European Society for Medical Oncology, MSK, Phenotype, Pharmacodynamics, Bolt, Oncology, SDS, Cancer, Therapy, Patient, Breast, Toxicity, ASCO, TLR, Pharmaceutical industry, Vaccine

BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.

Key Points: 
  • BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.
  • The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab.
  • The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).
  • Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Partnership, Therapy, Impact, Food, PARP2, WRN, PARP1, EDT, Trial of the century, Science, Data analysis, Patient, Automation, Machine learning, TLR 7, Engineering, Eikon, Drug discovery, Morgan, AI, TLR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, VCP, Antiandrogen, Pharmaceutical industry, IND

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Retrieved on: 
Thursday, August 10, 2023
Health, Oncology, Clinical Trials, Well, LLP, Drug, Therapy, Liver disease, Myeloid-derived suppressor cell, Hepatocellular carcinoma, Neoplasm, Clinical trial, Pancreas, MDSC, Hope, Uveal melanoma, Cancer, MTAC, Toxicity, Foley & Lardner, Cholangiocarcinoma, Immunotherapy, JJ, ASCO, Cooley LLP, Patient, Blood, Liver, Growth, TLR, FDA, Hand, Environment, Medtech, MD Anderson Cancer Center, Tumor microenvironment, Pharmaceutical industry, Medical imaging

TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).

Key Points: 
  • TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).
  • “Completing our merger with MedTech marks an important milestone in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and CEO of TriSalus.
  • Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting us to create value for them.
  • Robust Device Pipeline: TriSalus' technology pipeline includes a range of devices that use technology expected to substantially improve therapeutic delivery.

Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Wednesday, June 28, 2023
Janus, Patent, Therapy, Gastrointestinal tract, JAK, European Patent Office, European Public Prosecutor's Office, Antibody, Ulcerative colitis, Dicarboxylic acid, SAN, European Patent Convention, Integrin, Chemokine, Bacteria, B cell, TLR, Peptide, Disease, Pharmaceutical industry

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.
  • EP3554539B1 entitled “Treatment of a disease of the gastrointestinal tract with an integrin inhibitor,” European Patent No.
  • EP3554485B1 entitled “Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices,” European Patent No.
  • These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 180 issued patents and 145 pending applications.

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines

Retrieved on: 
Wednesday, June 28, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Beth Israel Deaconess Medical Center, SAB, Idera, Inc., Partnership, Central nervous system, University, University of Massachusetts, Therapy, Oxford, Schering-Plough, Therapeutic index, Oligonucleotide, ATX, RNA, IP, Antibody, Doctor of Philosophy, CNS, TCR, UCB, Patient, Peptide, Medicine, Biology, Liver, Merck, Ecosystem, Rare, Immunology, TLR, Alloy, Gene, Fine chemical, Vaccine, Pharmaceutical industry, Chemistry

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
  • Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC.
  • “The AntiClastic format has the potential to transform the development of antisense therapeutics,” said Agrawal.
  • In launching the AntiClastic ASO platform, Alloy is expanding into its third biologic modality, genetic medicines.

Tarsier Pharma Announces Publication of Review Article on Suppressing Inflammation for Treating Retinal Blinding Ocular Diseases, Highlighting dazdotuftide (TRS) as a Promising Therapeutic Candidate

Retrieved on: 
Monday, June 12, 2023
Biomedicine, Inflammation, Diabetes, Therapy, DME, AMD, Diabetic retinopathy, TRS, DR, Intravitreal injection, Retina, Potential New Boyfriend, Open access, DE, TEL, VEGF, Patient, Division, Treatment, Tarsier, NRP1, TLR, Pharmaceutical industry, Ophthalmology

The peer reviewed article "Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate", has been published as Open Access in the journal Biomedicines in May 2023.

Key Points: 
  • The peer reviewed article "Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate", has been published as Open Access in the journal Biomedicines in May 2023.
  • Dazdotuftide demonstrates the ability to target multiple inflammatory pathways, such as NRP1, TLR, and ACE-2, while simultaneously activating anti-inflammatory macrophages.
  • This groundbreaking approach positions dazdotuftide as a potential therapeutic option for effectively managing DR, DME, and AMD.
  • "Dazdotuftide represents an innovative therapeutic approach that addresses the unmet medical need for effective treatment of diseases such as AMD, DE, and DME," said Prof. Chowers. "

Excellent 12-Month Results from SELUTION SFA Trial Presented at JET

Retrieved on: 
Wednesday, May 31, 2023
DEB, Freedom, SUCCESS, CE marking, Paclitaxel, ISR, JET, BTK, De novo, DCB, Thrombosis, Death, Patient, SFA, IDE, TLR, Coronary artery disease, FDA, CLTI, Popliteal artery, Conference, Ferula assa-foetida, FIM, Safety, Pharmaceutical industry

GENEVA, May 31, 2023 /PRNewswire/ -- 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo.

Key Points: 
  • GENEVA, May 31, 2023 /PRNewswire/ -- 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo.
  • The prospective, multicenter single arm trial has involved 134 patients treated across 13 sites in Japan.
  • The primary endpoint of 12-month primary patency of the target lesion was achieved in 87.9% of patients.
  • This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe.

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Retrieved on: 
Monday, May 1, 2023
Cytosol, Toxicity, Therapy, NOD, Infection, Clinical trial, Cancer, American Association for Cancer Research, Research, Neoplasm, Inflammation, Decoy, Patient, PRR, Poster, TLR, Pharmaceutical industry, Vaccine

The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.

Key Points: 
  • The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.
  • Dr. Newman’s second talk, “Pre-Clinical Anti-HBV Activity with a Passively Targeted, Multi-TLR, NOD and STING Agonist,” which features the Company’s infectious disease research on its Decoy platform will be held on May 11th at 2:30PM.
  • Deep diving into the role that the microbiome plays in innate immune regulation to provide a more holistic overview of how the STING and TLR activation are regulated.
  • The event will be held at the Hilton Boston Back Bay in Boston.

EQS-News: Defence Therapeutics Inc.: DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER

Retrieved on: 
Monday, April 17, 2023
Therapy, Vaccination, Infection, USD, Messenger, ELISA, SOP, Animal, Engineering, Mouse, TLR, Vaccine, Defense

This first set of studies aims to validate a recently achieved milestone regarding the establishment of a mRNA conjugation protocol.

Key Points: 
  • This first set of studies aims to validate a recently achieved milestone regarding the establishment of a mRNA conjugation protocol.
  • The vaccine is admixed with the R848 adjuvant (a TLR ligand) and administered intramuscularly.
  • Once this analysis completed, another set of animals will be used to test the therapeutic potency of Defence’s AccumTM-mRNA vaccine.
  • Defence is developing its own novel AccumTM-linked mRNA vaccines for multiple cancer indications.

AM Best Affirms Credit Ratings of Talcott Life Re, Ltd.

Retrieved on: 
Thursday, March 30, 2023
Professional Services, Insurance, Finance, AM Best, LCC, ALL, ERM, Sixth Street Partners, Credit, Risk, AM, TLR, News, 6th Street, Risk management

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Talcott Life Re, Ltd. (TLR) (Hamilton, Bermuda).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Talcott Life Re, Ltd. (TLR) (Hamilton, Bermuda).
  • In December 2021, Allianz Life Insurance Company of North America announced reinsurance agreements with Resolution Life Group Holdings LP and Talcott Resolution Life Insurance Company (Talcott), the latter of which is affiliated with Sixth Street and TLR.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .